|
|||||||||||||||
|
||||||||||||||||||
Data:2009-12-12 2:34
Source: GF Securities Research
Strong multi-factor to stimulate the medical section of the stock market this year, pharmaceutical shares in the collective performance of a few would be, or has lagged far behind the other plate. Afternoon there is compensatory growth requirements, and according to statistical data show that in the three published quarterly, QFII appeared 180 A shares of the company's top ten shareholders of tradable shares of the column, a total of 2.614 billion shares held by A shares, pharmaceutical stocks to become QFII new favorite. Statistics show that three quarters of QFII holdings of the largest number of pharmaceutical shares of the Company, to 11. QFII big pharmaceutical stocks were also bullish undervalued for reasons. At the same time, health care reform is coming, it will bring no small plates medicine opportunities. Qianjiang Pharmaceutical (600,568) production of crystal brand eye drops product output, sales, sales and market share ranks first in the country the same trade, afternoon should focus on.
Ophthalmic market, large-scale eye disease present, China's total market size of more than 10 billion, but with people's working environment and living environment changes, a number of eye disease has emerged as the rapid growth momentum. Today, the Internet, computer office popularity led to the use eye drops to alleviate the growing demand for visual fatigue and to increase the percentage of 25% per year; and cataract, glaucoma and other serious eye diseases accompanied by the number of patients with an aging population increasingly The phenomenon of serious and numerous electronic products, the use of modern technology, which led to millions of patients annually, the number of growth, these phenomena will once again reflects the ophthalmic market in urgent need of development of great potential.
Qianjiang Pharmaceutical is a Chinese eye medicine first listed companies. In 1995, the company was rated as the State Council Development Research Center, "China's largest manufacturer of ophthalmic drugs," and was included in "China's most honor ceremony." Crystal brand eye drops product output, sales, sales and market share ranks first in the country the same trade; the country ranked the top six product yield drops, the companies are the forefront, in which cyclopropane gatifloxacin eye drops ranks first in the country, ranking second ofloxacin eye drops;'s national market share of ophthalmic drugs to reach more than 11%.
The company as a national production base of ophthalmic drugs, eye drops are developed and produced wide variety of different sectors of the whole, in the domestic pharmaceutical companies unique. Company plans to become the country's largest production base of drugs facial features, the company has a strong production and development capacity, mainly engaged in eye drops, injections, tablets, capsules, freeze-dried injection and other pharmaceutical products, production, sales operations, development and production of the Eye Drops more than 30 varieties, is a typical small-scale high-tech enterprise. The company has a modern workshop and international advanced automatic production line of eye drops, has a whole through the State Food and Drug Administration GMP certification.
Tian Quan Quotes worth looking forward to technical point of view, since the stock market since 2001, which has been a downward path. Share price has dropped from 36 yuan to 3 yuan more than the original price less than 1 / 10, shrinkage rate is appalling. However, since bottoming out in July 2005 has been 3.21 yuan, the stock's decline has been markedly improved, and then sideways into the low volume stage of amplification, the main financial intervention significantly. After a long period of rest, the main capital through stock reform of the plane broke through to a long-term suppression of the Unit's annual line. Followed by the formation of a wave of ferocious pulled nearly doubling of the stock market. Share reform, the main funding and is not directly pulled, instead of using repeated shocks ways to continue cleaning Fu Chou, it is noteworthy that the volume was not significantly larger, can be seen locking of excellent chips. However, in late September the unit was finally not contain himself, Liangnengpeige shares rose continued to enlarge, the main intention of funding pulled exposure is no doubt that the first few trading days shares a sudden downward Po Wei, but the back line after six months, quickly stabilized, at present not even close three-yang, the standard short-trap construct complete, a vast market outlook Tianquan Quotes worth the wait.
